Archive | Hot Mandates RSS feed for this section

Hot Investor Mandate: Austria Firm Invests Opportunistically In Life Science Deals

21 Mar

An investment firm based in Austria manages a total of EUR 50 million in capital, and invests in seed and early stage opportunities in Austria. The firm initially invests up to EUR 1 million, with further capital reserved for potential follow-on rounds.

The firm will consider investing in any area of life science technology, including biotech, medical devices, diagnostics, and also agtech and environmental biotech. The firm is open to investing in early-stage companies that have not yet commenced human clinical trials; however, the firm will only invest in companies that have a working prototype or animal data for their product. While the firm will consider any technology or indication area, the firm generally prefers not to invest in health apps, or in fields such as oncology that incur high costs for clinical development.

The firm focuses on investing in their local area close to Vienna. The firm is open to being a lead investor but prefers not to be the sole investor in a round; the firm syndicates with other VCs and other sources of capital.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Newly Established Healthcare Fund Seeks to Lead Investments in Cardiovascular, Ophthalmology, and Regenerative Medicine Companies

14 Mar

A newly established Healthcare focused fund with offices in USA, Europe, and China, is broadly focused in Life Sciences with strong preference for early stage opportunities. The senior team members have strong operating experience in biotech and pharma companies, and would like to lead investments and play active roles in their portfolio companies.

The firm is particularly keen on cardiovascular, regenerative medicine, and ophthalmology related opportunities. The firm is otherwise agnostic in regards to specific disease indications and is willing to look at all opportunities within the early stage, however diagnostics is currently considered as a low priority.

As the firm seeks to be an active lead investor, the firm strongly prefers a board seat in companies that they have invested in. Outside of the board requirement, the firm is looking for strong management teams that demonstrate the capability to move their technology forwards.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: International Firm Seeks to Partner with Novel Diagnostics Companies that Target Oncology, Metabolic Disease, Infectious Disease, etc.

14 Mar

An international firm conducts global business development and licensing searches in all stages of clinical diagnostics research and development, regardless of the technology involved. The firm employs a variety of deal structures including IP rights in- and out- licensing, product or technology co-development, and M&A.

The firm is interested in new technologies in point of care diagnostics, molecular diagnostics, tissue diagnostics, bioinformatics, and instrumentation, sequencing and associated software. The firm’s indications of interest include oncology, sepsis, pre-natal health and women’s health, bone metabolism, cardiovascular disease, diabetes and metabolic disease, kidney disease, infectious disease, and genetic disorders.

The firm has no specific company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

%d bloggers like this: